Research and Markets (http://www.researchandmarkets.com/research/7gdk6g/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identifies emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develops strategic initiatives by understanding the focus areas of leading companies
  • To identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome
  • To plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned:

  • 4D Pharma Plc
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Alba Therapeutics Corporation
  • Alfa Wassermann S.p.A
  • Allergan Plc
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • CJ HealthCare Corp.
  • Dong-A Socio Group
  • Enterome Bioscience SA
  • ImmusanT, Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Protagonist Therapeutics Inc.
  • RaQualia Pharma Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • SK Chemicals Co., Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Synergy Pharmaceuticals, Inc.
  • Synthetic Biologics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Yuhan Corporation

For more information visit http://www.researchandmarkets.com/research/7gdk6g/irritable_bowel